HomeMBIO • NASDAQ
add
Mustang Bio Inc
Previous close
$0.85
Day range
$0.78 - $0.90
Year range
$0.53 - $7.00
Market cap
6.19M USD
Avg Volume
285.81K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 670.00K | 2,676.92% |
Net income | -538.00K | 43.49% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -670.00K | -970.13% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 17.27M | 152.46% |
Total assets | 17.59M | 89.01% |
Total liabilities | 8.06M | -38.82% |
Total equity | 9.53M | — |
Shares outstanding | 1.69M | — |
Price to book | 0.15 | — |
Return on assets | -9.07% | — |
Return on capital | -17.36% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -538.00K | 43.49% |
Cash from operations | -1.72M | 13.97% |
Cash from investing | 0.00 | — |
Cash from financing | 0.00 | -100.00% |
Net change in cash | -1.72M | -158.46% |
Free cash flow | -2.00M | -29.97% |
About
Mustang Bio is an American clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency. Wikipedia
Founded
2015
Headquarters
Website
Employees
6
